Nondisabling relapses that occur early in the course of relapsing-remitting multiple sclerosis (RRMS) signal faster accumulation of disability relative to no early relapses, new research suggests.

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study ...

Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without ...

Significant advances have been made over the last 20 years in long-term immunomodulatory therapy of multiple sclerosis. However, the same cannot be said for the treatment of acute relapses, explain ...

A committee in the EU recommended that tolebrutinib, to be sold as Cenrifki, be approved for people with SPMS with no relapses for two years.

Roche Holding AG’s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage ...

Relapse isn’t inevitable, and it’s certainly a different story for every individual. However, it is very often part of the recovery journey. Garrett Tardif, the director of Admissions at Crestview ...

These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspryng® (satralizumab) reduced the risk of a new ...

A young man in recovery from addiction once gave me his perspective on the painful consequences of relapse: “It’s not the relapse that troubles me,” he said. “It’s the self-beating that comes ...